| breast cancer - adjuvant | breast cancer - HER2-positive | breast cancer - triple negative | |||||
| breast cancer - adjuvant | es-BC - HER2 negative - (neo)adjuvant (NA) | es-BC - TNBC - NA - all population | mBC - TNBC - L1 - all population | mBC - TNBC - L1 - PDL1 positive | mBC - TNBC - L2 - all population | mBC - TNBC - L2 - PDL1 positive | |
| pembrolizumab based treatment | |||||||
| pembrolizumab alone | KEYNOTE-522 | KEYNOTE-522 | KEYNOTE-119 ... | KEYNOTE-119 ... KEYNOTE-119 ... | |||
| pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamide | I-SPY2 | ||||||
| pembrolizumab plus SoC | KEYNOTE-355 ... | KEYNOTE-355 ... KEYNOTE-355 ... | |||||
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
